Pemetrexed is a multi-targeting antifolate cytotoxic drug and, within the last decade, has brought a new paradigm shift in treatment strategies for non-squamous non-small cell lung cancer (NSCLC). In the United States, pemetrexed has been approved three times by the Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic non-squamous NSCLC in 2004, 2008 and 2009. Indications were the use as a single agent for patients in whom any prior chemotherapy has failed, the use in combination with cisplatin for the first-line treatment and the use in maintenance treatment after platinum-doublet induction chemotherapy, respectively. Owing to the advantage of less cumulative toxicities, pemetrexed has become indispensable for switch-or continuation-maintenance therapy. These maintenance methods have superseded the conventional methods of the defined cycles of chemotherapy followed by drug holidays in the front-line chemotherapy. A recent topic is a challenge of further addition of any tolerable drug to continuation-maintenance by pemetrexed alone. Comparing recent randomized phase III studies (PRAMOUNT, AVAPERL and PointBreak), the addition of bevacizumab to a standard regimen of pemetrexed plus platinum induction has enabled more patients to receive maintenance therapy and continuation-maintenance by pemetrexed plus bevacizumab has brought about longer progression-free survival than the maintenance by either of the two drugs. However, further investigation and discussion are required on the viewpoints of overall survival benefit and cost-effectiveness of adding bevacizumab and also we have to explore reliable selection markers for such expensive drugs.
Introduction
Lung cancer accounts for the most frequent cancerrelated death in the world [1] , but is still incurable unless it is diagnosed in early stage. For patients with inoperably advanced stage disease and good performance status, chemotherapy is a standard strategy. Conventionally, four to six cycles of platinum-based doublet has been a standard 
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regimen in the first-line setting. Lung cancer is histologically categorized into two subtypes; non-small cell lung cancer (NSCLC) and small cell lung cancer. NSCLC accounts for more than 80% of all lung cancer cases, and is histologically further subdivided into adenocarcinoma, squamous cell carcinoma, large cell carcinoma and others.
Within the last decade, pemetrexed, a multi-targeting antifolate cytotoxic drug, has brought a paradigm shift in treatment strategies for non-squamous NSCLC. This drug primarily inhibits the following three enzymes involved in folate metabolism; thymidylate synthase (TS), dihydrofolate reductase and glycinamide ribonucleotide formyl transferase [2] . In lung cancer, pemetrexed has experienced three stages of indication approval by the Food and Drug Administration (FDA) in locally advanced or metastatic non-squamous NSCLC. At the beginning, pemetrexed established the practical evidences in the second-line setting for non-squamous NSCLC in 2004. In a randomized phase III study (JMEI) that compared pemetrexed (n=283) with docetaxel (n=288) in this clinical setting for NSCLC, pemetrexed maintained similar response rate (pemetrexed 9.1 vs. docetaxel 8.8%, p = 0.105), PFS (2.9 vs. 2.9 months, respectively; Hazard ratio (HR) = 0.97; 95% confidence interval (CI), 0.82 to 1.16; p = 0.759) and median OS (8.3 vs. 7.9 months, respectively; HR = 0.99; 95% CI, 0.82 to 1.2; non-inferiority p = 0.226). In addition, pemetrexed also showed significantly fewer adverse effects and improved tolerability [3] . As a result, pemetrexed received accelerated approval by the FDA in July 2004. Thus, pemetrexed monotherapy became one of the three approved regimens as the second-line treatment in patient with NSCLC, along with docetaxel and erlotinib. Thereafter, pemetrexed was promoted into the front-line regimen, and eventually has succeeded in securing an established position as a partner of platinum.
On the other hand, results from subgroup analyses of several clinical trials by histology have reproductively revealed that pemetrexed is less effective on squamous cell histology [4] [5] [6] . Thus, squamous cell lung cancer was excluded from the indication of pemetrexed. Small cell carcinoma is also a histology for whom pemetrexed is not recommended [7] .
More recently, pemetrexed has been approved as a key drug for maintenance therapy after the first-line platinumbased induction chemotherapy for non-squamous NSCLC because of the advantage of less cumulative toxicities. We herein review the roles and unresolved issues of pemetrexed in the treatment for non-squamous NSCLC. S; single-arm, R; Randomized, p2; phase II, NSCLC; non-small cell lung cancer, SQ; squamous cell carcinoma, inc.; including, CBDCA; carboplatin, AUC; an area under the concentration-time curve ( mg/ml min), PEM; pemetrexed, CDDP; cisplatin, , RR; response rate, DCR; disease control rate, TTP; time-to-progression time, PFS; progression free time, OS; overall survival, n.d.; not described, M; month.
Pemetrexed plus platinum without maintenance therapy in chemo-naïve patients
For chemo-naïve patients with NSCLC, a practical challenge of pemetrexed combined with platinum appeared in 2000, when the first phase II study of pemetrexed combined with cisplatin was published [8] . This study also validated the administration schedule of the intravenous infusion of both drugs on the first day of every 3 weekcycle, which has become a standard schedule of this combination regimen. The second approval of indication for NSCLC was in 2008, when the first evidence of pemetrexed combined with cisplatin in the first-line setting was published. A randomized phase III study (JMDB) demonstrated that pemetrexed plus cisplatin (n=862) was comparable with gemcitabine plus cisplatin (n=863) in response rate (30.6% for pemetrexed arm vs. 28.2% for gemcitabine arm), non-inferior in PFS (4.8 vs. 5.1 months, respectively; HR = 1.04; 95% CI, 0.94 to 1.15) and OS (10.3 vs. 10.3 months, respectively; HR = 0.94; 95% CI, 0.84 to 1.05), and better in tolerability, for chemo-naïve NSCLC patients [6] . This study also found that the OS of pemetrexed plus cisplatin was longer in patients with adenocarcinoma (n=847; 12.6 vs. 10.9 months, respectively; HR = 0.84; 95% CI, 0.71 to 0.99; p = 0.03) and large cell carcinoma (n=153; 10.4 vs. 6.7 months, respectively; HR = 0.67; 95% CI, 0.48 to 0.96; p = 0.03) histology, but shorter in patients with squamous cell carcinoma (n=473; 9.4 vs. 10.8 months, respectively; HR = 1.23; 95% CI, 1.00 to 1.51; p = 0.05) compared with gemcitabine plus cisplatin [9] (Table 1 ). This histological difference in efficacy of pemetrexed was also shown in the previous phase III study of second-line pemetrexed monotherapy [5] . Thus, pemetrexed has built up a priority position as the partner of platinum for non-squamous NSCLC.
As for a partner of pemetrexed, we have not reached a consensus on the matter which plutinum is better cisplatin or carboplatin. Carboplatin is practically more convenient than cisplatin because of advantages of the lower incidence of serious adverse effects such as severe emesis and nephrotoxicity. Carboplatin also started to be evaluated as a first-line partner with pemetrexed in 2005, when two phase II studies of combination therapy of pemetrexed and carboplatin showed favorable efficacies and toxicities [10, 11] . Because of those advantages of this drug, many studies challenged carboplatin to maintain quality-of-life (QoL) or treat frail patients. There were three unique randomized phase III studies, comparing pemetrexed plus carboplatin with gemcitabine plus carboplatin [12] , docetaxel plus carboplatin [13] and pemetrexed monotherapy [14] . The primary end-points of the former two studies were unique, and were health-related QoL during the first 20 weeks [12] and survival without grade 3 or 4 toxicity [13] , respectively. On the other hand, as is usual with phase III trial, the last study defined OS as the primary end-point, but characteristically accrued only frail patients with European Clinical Oncology Group (ECOG) performance status (PS) of 2 [14] . As a result of this study, combinationchemotherapy of pemetrexed with carboplatin (n=103) provided better response rate (24% vs. 10%; p = 0.032) and longer survival (PFS, 5.8 vs. 2.8 months; HR = 0.46; 95% CI, 0.35 to 0.63; p < 0.001 and OS, 9.3 vs. 5.3 months; HR = 0.62; 95% CI, 0.46 to 0.83; p = 0.001) than single-agent pemetrexed (n=102), despite of slightly additive adverse effects. A prospective single-arm phase II study also showed that carboplatin-based combination was feasible for elderly (age ≥ 70 years) patients maintaining good ECOG PS of 0-1 [15] (Table 2 ).
There was no study that directly compared carboplatin with cisplatin as a partner of pemetrexed. Although only one study randomly assigned enrolled patients to either pemetrexed plus carboplatin or pemetrexed plus cisplatin, this study did not compare these two treatment groups statistically [16] . Overall, considering the fact that a couple of studies of pemetrexed plus carboplatin targeted frail patients, there seems little difference in PFS and OS between these two platinum-based regimens (Fig.1) . Thus, the combination of pemetrexed and carboplatin could be not only a substitutive option of pemetrexed plus cisplatin for frail patients to whom cisplatin seems unfit, but also an alternative option for other patients.
Pemetrexed plus platinum in pretreated patients
There were two randomized phase II studies that compared pemetrexed monotherapy with pemetrexed plus carboplatin in the second-line setting. All patients in these two studies had received platinum-containing chemotherapy as the first-line regimen, but the detailed proportions of the previous first-line regimen, cisplatinbased or carboplatin-based, were unknown. In an Italian study (Gruppo Oncologico Italiano di Ricerca Clinica; GOIRC 02-2006), compared with pemetrexed alone (n=120), addition of carboplatin to pemetrexed (n=119) failed to improve response rate (12.6% for pemetrexed plus carboplatin vs. 12.5% for pemetrexed; odds ratio (OR) = 1.01; 95%CI = 0.47 to 2.17; p = 0.980), PFS (3.5 vs. 3.6 months; HR = 1.05; 95% CI = 0.81 to 1.36; p = 0.706) and OS (9.2 vs. 8.8 months; HR = 0.97; 95% CI, 0.73 to 1.35; p = 0.834) [17] . Contrarily, in another Dutch study (Nederlandse Vereniging Artsen voor Longziekten en Tuberculose Lung Cancer Group Trial 7; NVALT7), pemetrexed plus carboplatin (n=119) improved PFS (4.2 vs. 2.8 months; HR = 0.65; 95% CI = 0.49 to 0.85; p = 0.005) significantly, but not OS (8.0 vs. 7.6 months; HR = 0.85; 95% CI = 0.63 to 1.2; not significant) compared to pemetrexed alone (n=121) [18] . Consequently, a pooled analysis of 479 patients collected from these two studies showed that there was no significant difference between combination therapy and monotherapy in response rate (15% for pemetrexed plus carboplatin vs. 9% for pemetrexed; OR=1.72; 95% CI = 0.97 to 3.02; p = 0.062), PFS (3.9 vs. 3.0 months; HR = 0.85; 95% CI = 0.70 to 1.02; p = 0.07) and OS (8.7 vs. 8.2 months; HR = 0.90; 95% CI = 0.74 to 1.10; p = 0.316) [17] . Although other two singlearm phase II studies of pemetrexed plus carboplatin included many patients with squamous cell carcinoma histology or prior treatment history of 2 to 3 regimens, their results were apparently similar in efficacy and survival to those of the two randomized phase II described above [19, 20] . Overall, despite of lack of enough evidence, we should not expect additional effects of carboplatin to pemetrexed for pretreated patients. Pemterexed monotherapy is still a standard regimen for pretreated patients with nonsquamous NSCLC (Table 3) .
Pemetrexed plus platinum after EGFR-TKI failure
Three epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs); gefitinib [21, 22] , erlotinib [23, 24] and afatnib [25, 26] have been approved as a first-line treatment for patients with active EGFR mutations. There were seven randomized phase III trials that compared any EGFR-TKI with six cycles of platinum doublet for chemo-naïve patients with active EGFR mutations [21] [22] [23] [24] [25] [26] [27] . None of them defined OS as a primary endpoint. Considering five trials that reported OS and post-study treatment [23, [28] [29] [30] [31] , there is probably no significant difference in OS between EGFRTKIs and any platinum doublet chemotherapy as a first-line S; single-arm, R; Randomized, p3; phase III, p2; phase II, SQ; squamous cell carcinoma, inc.; including, CBDCA; carboplatin, AUC; an area under the concentration-time curve ( mg/ml min), PEM; pemetrexed, Bev; bevacizumab, CDDP; cisplatin, RR; response rate, DCR; disease control rate, ICR: completion rate of induction chemotherapy, MTR; transfer rate to maintenance therapy, PFS; progression free time, TTP; time-to-progression time, OS; overall survival, n.d.; not described, M; month.
regimen. Only LUX-Lung 3 study adopted pemetrexed plus cisplatin as a control regimen [25] , but did not allow nonprogressive patients by induction therapy to receive pemetrexed continuation-maintenance as well as crossover afatinib treatment as post-protocol EGFR-TKI therapy. Final OS result is coming soon. However, we should not simply conclude that afatinib should be used first without deep insights about post-protocol treatments, even if afatinib arm shows longer OS. The unresolved issue we would most like to clarify is whether PFS of platinumbased chemotherapy is different between first-line use and second-line use after failure of EGFR-TKI. Overall, pemetrexed plus platinum is probably an essential regimen like other platinum-doublet regimens after EGFR-TKI failure to treat EGFR-mutated patients.
Switch-maintenance and continuation-maintenance by pemetrexed monotherapy
The third induction approval was in 2009, when the FDA approved pemetrexed for maintenance use on a basis of a phase III study (JMEN) that had demonstrated a survival benefit when switch-maintenance of pemetrexed monotherapy was introduced after four cycles of platinumbased induction chemotherapy [32] . Pemetrexed switchmaintenance significantly prolonged PFS (4.3 vs. 2.6 months; HR = 0.50; 95% CI = 0.42 to 0.61; p < 0·0001) and OS (13.4 vs. 10.6 months; HR = 0.79; 95% CI = 0.65 to 0.95; p = 0.012) compared to placebo from the randomization after completion of induction therapy. These benefits were more remarkable in non-squamous NSCLC (PFS; 4.5 vs. 2.6 months; HR = 0.44; 95% CI = 0.36 to 0.55; p < 0.0001, and OS; 15.5 vs. 10.3 months; HR = 0.70; 95% CI = 0.56 to 0.88; p = 0.002). This study also answered which is the better timing, 'early' or 'delayed', of administration of the next chemotherapy after the first-line chemotherapy, because switch-maintenance is almost the same as the early administration of the second-line chemotherapy. Pemetrexed could be administered only in 18% of patients in the placebo arm as a post-protocol therapy, which meant that 82% of them had actually missed S; single-arm, R; Randomized, p3; phase III, p2; phase II, SQ; squamous cell carcinoma, inc.; including, CBDCA; carboplatin, AUC; an area under the concentration-time curve ( mg/ml min), PEM; pemetrexed, Bev; bevacizumab, CDDP; cisplatin, RR; response rate, DCR; disease control rate, ICR: completion rate of induction chemotherapy, MTR; transfer rate to maintenance therapy, PFS; progression free time, TTP; time-to-progression time, OS; overall survival, n.d.; not described, M; month.
the chance to receive pemetrexed therapy. From this fact, pemetrexed switch-maintenance is recommended as early second-line if patients maintain good PS and their diseases have not progressed after platinum-doublet induction.
We looked upon 2012 as more important year for patients with non-squamous NSCLC, when a phase III study (PARAMOUNT) presented the first and only evidence of survival benefit by continuation-maintenance of pemetrexed monotherapy for non-progressive patients after four cycles of pemetrexed plus cisplatin. Pemetrexed continuation-maintenance significantly improved PFS (4.4 vs. 2.8 months; HR = 0.60; 95% CI = 0.50 to 0.73; p < 0.001) and OS (13.9 vs. 11.0 months, respectively; HR = 0.78; 95% CI = 0.64 to 0.96, p = 0.0195) compared to placebo from randomization after the completion of induction therapy [33, 34] .
The practical impacts of two maintenance strategies were very different. Most physicians would hesitate to switch drugs even after effective and well-tolerable induction chemotherapy. In contrast, continuationmaintenance is reasonable when both favorable response and tolerable adverse effects were observed during induction chemotherapy. The continuation-maintenance by pemetrexed has superseded the conventional methods of the defined cycles of chemotherapy followed by drug holidays in the front-line chemotherapy, which are currently accepted only for elderly or frail patients. Recently, four phase II studies of pemetrexed plus platinum followed by pemetrexed continuation-maintenance were reported [35] [36] [37] [38] . Three of them were conducted in Japan and investigated carboplatin-based induction regimen [36] [37] [38] . Despite of similar or slightly improved PFS compared with the past studies, the OSs of the three Japanese studies surprisingly reached nearly two years, much longer than those of the historical records. (Table 4 ) Thus, pemetrexed continuation-maintenance is undoubtedly recommended. Moreover, carboplatin is thought to have an equal power to cisplatin as the induction-partner of pemetrexed in the regimen containing pemetrexed continuation-maintenance.
Biomarker predicting the benefit of pemetrexed
No established marker predicting the benefit by pemetrexed maintenance therapy has been found. TS expression is presumably the most promising predictive biomarker for clinical outcomes of pemetrexed-containing chemotherapy. Besides many in vitro experiments and retrospective clinical studies that evaluated the association between efficacy of pemetrexed-containing treatment and TS expression of protein and mRNA, gene copy number or gene polymorphisms, a latest prospective blinded assessment of phase II study revealed that low expression of nuclear TS at protein and mRNA levels was associated with longer PFS. In this study, there was a significant difference in PFS between patients with low TS expression (n=40) and those with high expression (n=20) (7.1 vs. 2.6 months, respectively; HR = 0.28; 95% CI = 0.16 to 0.52; p = 0.0015). This study used a current standard regimen of four cycles of induction pemetrexed plus cisplatin followed by pemetrexed maintenance therapy in non-progressive patients with non-squamous NSCLC [39] . On the other hand, an updated subgroup analyses of final OS in PARAMOUNT did not find any association of longer OS with adverse events during induction therapy, tumor response to induction therapy (complete or partial response vs. stable disease) and the interval time from end of induction therapy to start of maintenance therapy (< 7 days vs. 7 to 30 days), except for a baseline characteristics of ECOG PS (grade 0 vs. grade 1) [40] . Despite of a small sample size (n=34), our study detected the following three predictive factors for longer PFS from enrollment before induction therapy; 1) positive EGFR mutation status (vs. negative/unknown, relative risk = 0.17; 95% CI = 0.03 to 0.85; p = 0.03), 2) better Karnofsky PS (KPS) grade of 80 to 100 (vs. KPS 70, relative risk = 0.18; 95% CI = 0.04 to 0.69; p = 0.01) and 3) longer time to the best response achievement from enrollment (relative risk = 0.69, 95% CI = 0.52 to 0.92; p = 0.01) [41] . Considering the third predictive factor, we set up a hypothesis that patients with slow and late response to induction therapy retain a long response even after the introduction of maintenance therapy, because pemetrexed plays an important role in this population. Contrastively, patients with rapid and early response to induction therapy experience earlier progression disease in the following maintenance phase, because carboplatin is indispensable for these patients [41] . Similar phenomenon is observed in the survival curves in PARAMOUNT study. The PFS curve of pemetrexedmainenance arm is closely superimposed over placebo arm for the first 1.5 months from randomization, indicating that cisplatin but not pemetrexed was the key drug in the patients who experienced early disease progression after randomization [25, 26] . It would be beneficial if we could select patients who are really indicated for pemetrexed maintenance therapy. Therefore, further analyses of true predictive factors for pemetrexed efficacy are warranted.
Additional effects of bevacizumab on pemetrexed
In addition to pemetrexed, bevacizumab and erlotinib have been also reported to be promising for maintenance use in non-progressive patients after induction chemotherapy. Bevacizumab is a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF). This drug was shown to prolong both PFS (paclitaxel plus carboplatin plus bevacizumab (n=417) 6.2 vs. paclitaxel plus carboplatin alone (n=433) 4.5 months; HR = 0.66; 95% CI = 0.57 to 0.77; p < 0.001) and OS (12.3 vs. 10.3 months, respectively; HR = 0.79; 95% CI = 0.67 to 0.92; p = 0.003) in previously untreated patients with nonsquamous NSCLC when combined with paclitaxel plus carboplatin and subsequently maintained until progressive disease or intolerable adverse effects (ECOG4599) [42] , while OS prolongation was not detected when combine with cisplatin plus gemicitabine (AVAiL) [43] . Erlotinib is one of reversible EGFR tyrosine kinase inhibitors. A phase III study (SATURN) demonstrated that erlotinib switchmaintenance had brought survival benefit after platinumbased induction chemotherapy in EGFR mutationunselected NSCLC population [44] .
A recent trend of challenge is further addition of any tolerable drug to continuation-maintenance of pemetrexed alone. Namely, there are three possible doublet combination; erlotinib plus bevacizumab, pemetrexed plus erlotinib, and pemetrexed plus bevacizumab.
A randomized phase III study (BeTa) compared erlotinib plus bevacizumab with erlotinib alone as the second-line regimen. As a result of this study, addition of bevacizumab to erlotinib did not improve OS, the primary endpoint (erlotinib plus bevacizumab 9.3 vs. erlotinib plus placebo 9.2 months; HR = 0.97; 95% CI = 0.80 to 1.18; p = 0.7583), despite of improvement in PFS (3.4 vs. 1.7 months, respectively; HR = 0.62; 95% CI = 0.52 to 0.75) [45] . A phase III study (ATLAS) compared maintenance of erlotinib plus bevacizumab with bevacizumab alone for non-progressive patients with NSCLC after four cycles of bevacizumab plus platinum-based chemotherapy chosen by investigators from six optional regimens. The addition of erlotinib to bevacizumab improved PFS from randomization (bevacizumab plus erlotinib (n=319) 4.8 vs. bevacizumab plus placebo (n=317) 3.7 months; HR = 0.71; 95% CI = 0.58 to 0.86; p < 0.001) but not OS (14.4 vs. 13.3 months, respectively; HR = 0.92; 95% CI = 0.70 to 1.21; p = 0.5341) [46] . This study defined PFS as the primary endpoint and was thought to be underpowered to detect a possible difference in OS. However, considering the slight difference of 1.1 months in median OS, we cannot expect the significant clinical benefit of this combination as a maintenance regimen so much.
Several phase II studies has recently reported the results of the combination of pemetrexed plus erlotinib in the second-line setting. We previously reviewed pemetrexed plus erlotinib in the second-line setting in this journal (in press). Briefly, this combination regimen is controversial, and we doubted an additional survival effect of erlotinib to pemetrexed. There has been no study of combination maintenance therapy of pemetrexed plus erlotinib.
Unlike the other two combination patterns, pemetrexed plus bevacizumab seems promising as a maintenance regimen on the basis of a phase III study (AVAPERL) [47] , but controversial from another phase III study (PointBreak) [48] . AVAPERL compared maintenance bevacizumab alone (n=125) with maintenance pemetrexed plus bevacizumab (n=128) for non-progressive patients with non-squamous NSCLC after four cycles of the firstline induction triplet chemotherapy of cisplatin, pemetrexed and bevacizumab. The addition of pemetrexed to bevacizumab significantly prolonged PFS from randomization (pemetrexed plus bevacizumab 7.4 vs. bevacizumab alone 3.7 months; HR = 0.57; 95% CI = 0.44 to 0.75, p <0.0001) but not OS (17.1 vs. 13.2 months, respectively; HR = 0.87; 95% CI = 0.63 to 1.21; p = 0.29) [40, 47] . This study is also thought to be underpowered to evaluate OS, because the primary endpoint was PFS. However, considering the difference of 3.9 months in OS between the two groups, survival benefit is expected in this combination. On the other hand, PointBreak compared pemetrexed plus carboplatin plus bevacizumab followed by maintenance pemetrexed plus bevacizumab (n=472) with paclitaxel plus carboplatin plus bevacizumab followed by maintenance bevacizumab alone (n=467) in patients with non-squamous NSCLC. Although the former regimen was superior in PFS from randomization to the latter regimen (6.0 vs. 5.6 months, respectively; HR = 0.83; 95% CI = 0.71 to 0.96; p = 0.012), there was no significant difference in OS, the primary endpoint, between the two regimens (12.6 vs. 13.4 months, respectively; HR = 1.00; 95% CI = 0.86 to 1.16; p = 0.949) [48] .
Comparing two types of regimen with or without bevacizumab (Table 4 vs. Table 5 and 6, and Fig.1 ), the addition of bevacizumab to induction chemotherapy apparently improved the maintenance transition rate by nearly 10%, but the additional bevacizumab was unlikely to prolong OS. Thus, it remains undetermined if the firstline induction and subsequent maintenance therapy should be indispensably accompanied by both pemetrexed and bevacizumab or not. We have to wait for the result of two ongoing large-scale randomized phase III studies. One compares maintenance therapy among bevacizumab alone, pemetrexed alone and a combination of these two drugs after induction by carboplatin plus paclitaxel plus bevacizumab (ECOG5508; ClinicalTrials.gov identifier; NCT01107626). The other compares maintenance therapy between bevacizumab alone and a combination of pemetrexed plus bevacizumab after induction by carboplatin plus pemetrexed plus bevacizumab (WJOG5610L COMPASS; UMIN000004194). Further investigation and discussion are required for combination of pemetrexed with bevacizumab from various viewpoints, including cost-effectiveness.
Conclusions and Future directions
It is quite natural that pemetrexed is indispensable in the front-line regimen for non-squamous NSCLC, because this drug is surely suitable for a combination partner of induction and a maintenance drug, owing to its effectiveness and low cumulative toxicity. At the same time, the recent first-line regimen shows a tendency to include more drugs by means of multi-drug combination and maintenance therapy. Pemetrexed is one of highly expensive anti-tumor drugs, as well as bevacizumab. Like EGFR mutation status for EGFR tyrosine kinase inhibitors, we have to explore reliable selection markers to select suitable patients who can really benefit from such expensive drugs.
